Regular paperRelationship between early and late normal-tissue injury after postmastectomy radiotherapy
References (25)
- et al.
Clinical radiobiology of malignant melanoma
Radiother. Oncol.
(1989) - et al.
Fractionation sensitivity of a clinical endpoint: Impaired shoulder movement after post-mastectomy radiotherapy
Int. J. Radiat. Oncol. Biol. Phys.
(1989) - et al.
Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single-follow-up clinical study
Radiother. Oncol.
(1989) - et al.
Fractionation sensitivity and latency of telangiectasia after postmastectomy radiotherapy: a graded response analysis
Radiother. Oncol.
(1990) - et al.
Dose-time relationships for postirradiation cutaneous telangiectasia
Int. J. Radiat. Oncol. Biol. Phys.
(1977) - et al.
Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships
Int. J. Radiat. Oncol. Biol. Phys.
(1982) The progression rate of late radiation effects in normal tissues and its impact on dose-response relationship
Radiother. Oncol.
(1989)- et al.
The influence of fraction size in radiotherapy on the late normal tissue reaction. II. Comparison of the effects of daily and twice-a-week fractionation on human skin
Int. J. Radiat. Oncol. Biol. Phys.
(1984) - et al.
Repair capacity and kinetics of human skin during fractionated radiotherapy: erythema, desquamation, and telangiectasia after 3 and 5 years follow-up
Radiother. Oncol.
(1989) - et al.
Some methodological problems in estimating radiobiological parameters from clinical data. Alpha/beta ratios and electron RBE for cutaneous reactions in patients treated with postmastectomy radiotherapy
Acta Oncol.
(1988)
Direct estimation of latent time for radiation injury in late-responding normal tissues: gut, lung and spinal cord
Int. J. Radiat. Biol.
(1989)
New options in direct analysis of dose-response data
Int. J. Radiat. Biol.
(1990)
Cited by (165)
Late toxicities management
2023, Palliative Radiation OncologyOutcomes in Patients Treated with Post-mastectomy Chest Wall Radiotherapy without the Routine Use of Bolus
2018, Clinical OncologyCitation Excerpt :The theoretical rationale behind the use of bolus in PMRT is to increase radiotherapy dose to the skin and dermal lymphatics, thereby reducing the risk of chest wall recurrences (CWR). However, bolus can lead to an increase in acute and late skin toxicities [4], and in some cases, significant moist desquamation, resulting in the early cessation of treatment and potentially inferior local control [5,6]. The routine use of bolus during PMRT remains a controversial issue, with limited clinical data to guide its optimal use.
A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation
2018, International Journal of Radiation Oncology Biology PhysicsLate cutaneous effects of a local potent steroid during adjuvant radiotherapy for breast cancer
2017, Clinical and Translational Radiation OncologyTen years results of the Canadian breast intensity modulated radiation therapy (IMRT) randomized controlled trial
2016, Radiotherapy and Oncology
Copyright © 1991 Published by Elsevier Ireland Ltd.